



References

- Bel EH, et al. *N Engl J Med*. 2014;371(13):1189-1197.
- Bice JB, et al. *Ann Allergy Asthma Immunol*. 2014;112(2):108-115.
- Bjerner L, et al. *Eur Resp J*. 2014;44(suppl 58):P299.
- Bleecker ER, et al. *Lancet*. 2016;388(10056):2115-2127.
- Castro M, et al. *Am J Respir Crit Care Med*. 2011;184(10):1125-1132.
- Castro M, et al. *Lancet Respir Med*. 2015;3(5):355-366.
- Centers for Disease Control and Prevention (CDC).
https://www.cdc.gov/asthma/most_recent_data.htm.
- Chest Foundation. SevereAsthmaTreatments.Chestnet.org.
- Chung KF, et al. *Eur Resp J*. 2014;43:343-373.
- Cinqair [package insert]. Frazer, PA: Teva Pharmaceutical Industries Ltd; June 2016.
- Corren J, et al. *Chest*. 2016;150(4):799-810.
- Corren J, et al. *Eur Resp J*. 2014;44(suppl 58):4673.
- Corren J. *Discov Med*. 2012;13(71):305-312.
- D'Erme AM. *Drug Design Dev Ther*. 2017;11:1473-1480.
- Fasenra [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2017.
- Gauthier M, et al. *Am J Respir Crit Care Med*. 2015;192(6):660-668.
- Global Initiative for Asthma. <https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/>.
- Haldar P, et al. *N Engl J Med*. 2009;360(10):973-984.
- Hanania NA, et al. *Am J Respir Crit Care Med*. 2013;187(8):804-811.
- Hanania NA, et al. *Ann Intern Med*. 2011;154:573-582.
- Humbert M, et al. *Eur Resp J*. 2018;51(5).
- Humbert M, et al. *J Allergy Clin Immunol Pract*. 2014;2(5):525-536.e1
- Israel E, et al. *N Engl J Med*. 2017;377(10):965-976.
- Kim H, et al. *Allergy Clin Immunol*. 2017;13:48.
- Kolbeck R, et al. *J Allergy Clin Immunol*. 2010;125(6):1344-1353.
- Kouro T, et al. *Int Immunol*. 2009;21(12):1303-1309.

Updates in Precision Medicine:
Elevating the Treatment of
Severe Eosinophilic Asthma



- Leckie MJ, et al. *Lancet*. 2000;356(9248):2144-2148.
- Miranda C, et al. *J Allergy Clin Immunol*. 2004;113(1):101-108.
- Mukherjee M, et al. *Am J Respir Crit Care Med* 2018;197(1):38-46.
- Nair P, et al. *N Engl J Med*. 2009;360(10):985-993.
- Nair P, et al. *N Engl J Med*. 2017;376(25):2448-2458.
- National Heart, Lung, and Blood Institute.
https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln_1.pdf.
- NCT01290887
(<https://clinicaltrials.gov/ct2/show/NCT01290887?term=asthma%2C+reslizumab%2C+3085&rank=1>)
- Nucala [package insert]. Research Triangle Park, NC: GlaxoSmithKline LLC; December 2017.
- Ortega HG, et al. *N Engl J Med*. 2014;371(13):1198-1207.
- Pavord ID, et al. *Lancet*. 2012;380(9842):651-659.
- Pelaia G, et al. *Nature Rev Drug Discov*. 2012;11(12): 958–972.
- Rabe KF, et al. *N Engl J Med*. 2018;378(26):2475-2485.
- Schumann C, et al. *Clin Respir J*. 2012;6:215-227.
- Wenzel SE. *Lancet*. 2006;368(9537):804-813.
- Xolair [package insert]. South San Francisco, CA: Genentech, Inc.; May 2018.
- Ziegler SF, et al. *Nat Immunol*. 2010;11(4):289-293.